I-Mab, a global biotech company listed on NASDAQ under the ticker IMAB, has announced the pricing of a $65 million underwritten offering of American Depositary Shares (ADSs). The offering consists of 33,333,334 ADSs, representing 76,666,668 ordinary shares, each priced at $1.95. The company plans to use the proceeds to fund clinical development of its pipeline products, including a Phase 2 trial of givastomig, and for general corporate purposes. The offering, set to close on August 5, 2025, is led by Leerink Partners with BTIG and Lucid Capital Markets also participating. A prospectus supplement has been filed with the SEC and is available for public access.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.